Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.
about
Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumoniaHuman recombinant activated protein C for severe sepsisHuman recombinant protein C for severe sepsis and septic shock in adult and paediatric patientsHuman recombinant activated protein C for severe sepsisHuman recombinant activated protein C for severe sepsisPolyphosphate and omptins: novel bacterial procoagulant agentsCoagulation in sepsis: all bugs bite equallyDrotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.Pancreatic injury in patients with septic shock: A literature reviewSepsis and disseminated intravascular coagulationInflammation and haemostasisThe coagulopathy of acute sepsisHost innate immune responses to sepsisProposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and HemostasisCoagulation abnormalities in critically ill patientsAssessment of the interplay between blood and skin vascular abnormalities in adult purpura fulminansHyperresponsiveness of mice deficient in plasma-secreted sphingomyelinase reveals its pivotal role in early phase of host responseDrotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysisPractical aspects of treatment with drotrecogin alfa (activated)Hemostatic abnormalities in critically ill patients.Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury.Hemostatic Changes Associated With Increased Mortality Rates in Hospitalized Patients With HIV-Associated Tuberculosis: A Prospective Cohort StudyCombination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational studyAnother step in improving the diagnosis of disseminated intravascular coagulation in sepsis.A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis.New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study.The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patientsDisseminated intravascular coagulation: a review for the internist.Mortality predictors in renal transplant recipients with severe sepsis and septic shock.Thromboelastometry (TEM) findings in disseminated intravascular coagulation in a pig model of endotoxinemia.Low dose endotoxin priming is accountable for coagulation abnormalities and organ damage observed in the Shwartzman reaction. A comparison between a single-dose endotoxemia model and a double-hit endotoxin-induced Shwartzman reaction.Is antithrombin treatment of disseminated intravascular coagulation a quixotic goal?Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock.Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation.The efficacy and safety of different anticoagulants on patients with severe sepsis and derangement of coagulation: a protocol for network meta-analysis of randomised controlled trials.Drotrecogin alpha: a rational approach to the treatment of submassive pulmonary embolism?Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism.Histones Induce the Procoagulant Phenotype of Endothelial Cells through Tissue Factor Up-Regulation and Thrombomodulin Down-Regulation.Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
P2860
Q21194921-84A40C57-5180-48BA-A76C-F01BA873B063Q24201123-5EFE9737-CFC2-47C6-B063-73B8BA15C273Q24202128-A9B2E469-DA9A-412B-8FF4-1435996CA627Q24235181-1C83A9E0-64A2-4D10-84A0-CF60AAF0796FQ24242859-F06D873F-2E9E-4480-96E1-DF2800E323D9Q24629548-2086778D-38E0-41D5-A97B-940E67D07F37Q24805503-EB64E786-35B5-4F13-B2C3-8FE5ADB8DB83Q24810495-726D2F5F-10B8-4681-946A-3C2F09166F9EQ26738929-B61A6748-B930-482F-8A52-81AAFF5F5F6EQ26751555-635F3114-4F12-4CB0-A3AC-94C43C48AB99Q26823258-41AEE74A-5B67-46F4-A693-23C6ABE7CA70Q26826950-02F41F54-05B8-4D84-A2A4-A619769F685AQ26864635-98D0F550-E1DE-4648-9809-846074EC21E2Q28076449-CE446CB6-ADE3-4310-B5F3-C52B0AC98DA9Q28199912-0CE91DEF-E95F-4A81-955C-A2DBC89A5968Q28296136-710E504A-318E-4F91-BFFF-447BA2B82524Q30531999-B307F1DF-E7A5-40EB-B534-F4898A02CC32Q33288889-D9DB9AE4-EF35-4E31-98C4-9C8B2BBBD220Q33378616-C6B8DAE9-2000-4A58-AC4D-50534C206BD2Q33419474-142BCA4D-4BA4-4468-B3E4-3841BB6CDF87Q33426245-70E13EC8-689C-4E7C-86CC-4C580ADF741EQ33712746-E55E3AF8-181E-4B3C-8C15-CA9A119FF28FQ33750809-F184B1BF-5CAD-448C-BAB1-7DC6FBA9A80EQ33752101-A7DBC9E7-0ED5-4FE0-A4F5-CB08AEC84517Q33752182-D0F4B456-1B83-4B61-B1E1-2087E0251B37Q33754477-0392A340-FCFA-4AE2-B51D-8E4916004CD3Q34257657-FE31A6BE-4FAB-4201-8EFC-260DD253EF66Q34302117-F904FA8E-E11B-4A6A-80D2-0CC75AF35C54Q34450365-CA341BFB-5A3D-4C60-9D55-D7107C882B8AQ34699548-A5B747D7-9E70-4326-BFF8-D8565325182EQ35024541-0FE9E32C-3AE8-41CF-8940-56EB6A89D0A9Q35091715-EBC861D2-FB45-468E-8078-2C43C20A4432Q35107079-459E4AFD-5BE5-48D9-8592-B9AAA4EFD729Q35107098-47EDF089-61A5-4CB5-B5AE-CBB55A81E15DQ35532746-2D87603D-F162-492E-8A8F-CCB79C72D45DQ35566987-913FFADC-C6A6-4CF7-BDAB-E3346103D125Q35567223-FC4CDD8C-C8EE-429B-B164-954859FB79C7Q36040066-0EED6B41-BE3B-4C60-8E46-C19209037089Q36349735-092A40CF-820B-4704-B5AC-20AB44D42C1EQ36715005-55D18D5F-2A2D-4DD6-9C72-4C713168213C
P2860
Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Treatment effects of drotrecog ...... ted intravascular coagulation.
@en
Treatment effects of drotrecogin alfa
@nl
type
label
Treatment effects of drotrecog ...... ted intravascular coagulation.
@en
Treatment effects of drotrecogin alfa
@nl
prefLabel
Treatment effects of drotrecog ...... ted intravascular coagulation.
@en
Treatment effects of drotrecogin alfa
@nl
P2093
P2860
P1476
Treatment effects of drotrecog ...... ted intravascular coagulation.
@en
P2093
D P Sundin
J T Brandt
J-F Dhainaut
P2860
P304
P356
10.1111/J.1538-7836.2004.00955.X
P577
2004-11-01T00:00:00Z